Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories around the world. The Company's segments include New Zealand, Australia, Asia and Rest of World. The Company's product portfolio targets various therapeutic areas, such as pain, eyecare, vitamins, allergy, gastrointestinal, dermatology and hospital. Its products include Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Combolieve Day/Night, Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, VitAPOS, Ferro-liquid, FerroTab, Ferro-F, Ferro-sachets, Lipo VitC, Lipo VitD, CalciTab, Loraclear, Histaclear, Fexaclear, Levoclear, Allersoothe, Lorapaed, Becloclear, Steroclear, Gastrosoothe/Forte, LaxTab, Micolette, Nausicalm, DiaRelieve, Crystaderm, Crystawash Hand Sanitizer, Crystasoothe, ZoRub anti-chafing, Decazol, MycoNail and others.
- Revenue in NZD (TTM)140.55m
- Net income in NZD17.06m
- Incorporated1997
- Employees107.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fuji Pharma Co., Ltd. | 439.57m | 32.89m | 336.03m | 1.56k | 10.03 | 0.7027 | 4.96 | 0.7644 | 110.81 | 110.81 | 1,480.81 | 1,580.96 | 0.4971 | 1.51 | 2.55 | 23,061,540.00 | 3.72 | 4.48 | 5.32 | 5.89 | 40.55 | 42.80 | 7.49 | 7.64 | 0.8779 | -- | 0.4375 | 30.86 | 4.22 | 0.022 | 10.86 | -3.97 | 51.78 | 7.84 |
| Amrutanjan Health Care Ltd | 75.07m | 8.14m | 337.87m | 647.00 | 41.61 | -- | 37.00 | 4.50 | 14.30 | 14.30 | 131.85 | -- | -- | -- | -- | 5,964,019.00 | -- | 18.30 | -- | 22.82 | 53.11 | 54.97 | 10.84 | 13.46 | -- | 118.34 | -- | 21.83 | 21.93 | 13.32 | 9.80 | 23.79 | 43.89 | 33.13 |
| AVE Science & Technology Co Ltd | 48.51m | 6.43m | 338.95m | 508.00 | 52.68 | 3.03 | -- | 6.99 | 0.4068 | 0.4068 | 3.07 | 7.07 | 0.3916 | 2.23 | 22.36 | 410,547.70 | 5.19 | -- | 5.66 | -- | 52.87 | -- | 13.26 | -- | 5.86 | -- | 0.00 | -- | 16.91 | -- | 3.90 | -- | -- | -- |
| Gufic BioSciences Ltd | 132.24m | 15.93m | 339.38m | 1.38k | 21.30 | -- | 17.47 | 2.57 | 8.45 | 8.45 | 70.14 | -- | -- | -- | -- | 4,918,800.00 | -- | 12.07 | -- | 26.78 | 52.82 | 44.45 | 12.04 | 8.73 | -- | 19.67 | -- | 1.54 | 59.76 | 24.51 | 116.68 | 60.42 | 84.54 | 14.87 |
| Mayne Pharma Group Ltd | 356.56m | -366.50m | 346.06m | 900.00 | -- | 0.4157 | -- | 0.9706 | -4.12 | 0.965 | 4.01 | 9.05 | 0.2244 | 2.02 | 1.54 | -- | -23.77 | -11.77 | -30.34 | -13.86 | 27.80 | 50.88 | -105.94 | -41.98 | 1.15 | -5.07 | 0.0924 | -- | 5.93 | -5.78 | -26.33 | -- | -59.47 | -- |
| Koa Shoji Holdings Co Ltd | 258.61m | 28.79m | 347.10m | 303.00 | 12.06 | 1.45 | 9.34 | 1.34 | 59.47 | 59.47 | 534.22 | 493.65 | 0.7933 | 6.18 | 2.39 | 69,851,920.00 | 8.83 | 6.69 | 11.06 | 8.42 | 28.20 | 27.70 | 11.13 | 9.06 | 3.27 | 68.98 | 0.1459 | 21.46 | 14.24 | 6.11 | 10.41 | 15.59 | -26.49 | -- |
| AFT Pharmaceuticals Ltd | 140.55m | 17.06m | 351.30m | 107.00 | 20.31 | 6.01 | 18.88 | 2.50 | 0.1649 | 0.1649 | 1.35 | 0.5571 | 1.21 | 2.08 | 5.22 | 1,313,561.00 | 14.70 | 6.25 | 23.32 | 10.24 | 45.36 | 45.57 | 12.14 | 4.88 | 0.6211 | 7.09 | 0.4142 | 0.00 | 15.22 | 13.49 | 161.36 | -- | 49.74 | -- |
| Jacobson Pharma Corporation Ltd | 338.67m | 47.63m | 362.50m | 1.80k | 7.54 | 0.6926 | 4.04 | 1.07 | 0.1219 | 0.1219 | 0.8672 | 1.33 | 0.3361 | 2.80 | 5.95 | 957,651.50 | 5.10 | 4.96 | 6.65 | 6.88 | 41.39 | 41.41 | 15.17 | 13.74 | 3.09 | 10.16 | 0.3414 | 32.46 | 10.35 | 4.90 | 2.28 | -0.186 | -7.11 | 12.02 |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 30 Apr 2022 | 4.78m | 4.56% |
| Guardians of New Zealand Superannuationas of 30 Apr 2022 | 1.65m | 1.57% |
| FCA Corp.as of 31 Jan 2023 | 46.00k | 0.04% |
| Dimensional Fund Advisors LPas of 02 Mar 2023 | 42.87k | 0.04% |
